Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Classical hematology 1

Conditions

Anemia, Refractory, with Excess of Blasts 50Myelodysplastic Syndromes 40Leukemia, Myeloid, Acute 34Leukemia, Myelomonocytic, Chronic 33Leukemia 31Precursor Cell Lymphoblastic Leukemia-Lymphoma 26Myeloproliferative Disorders 18Congenital Abnormalities 17Leukemia, Lymphocytic, Chronic, B-Cell 16Anemia, Refractory 15Blast Crisis 14Anemia 14Myelodysplastic-Myeloproliferative Diseases 10Lymphoma, Non-Hodgkin 10Leukemia, Myeloid, Chronic-Phase 10Leukemia, Myeloid, Accelerated Phase 9Leukemia, Megakaryoblastic, Acute 9Leukemia, Erythroblastic, Acute 9Neoplasms 8Lymphoma, Follicular 8Lymphoma 8Leukemia, Myelomonocytic, Acute 8Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 8Leukemia, Monocytic, Acute 8Anemia, Aplastic 8Lymphoma, Large B-Cell, Diffuse 7Hodgkin Disease 7Thrombocytopenia 6Multiple Myeloma 6Lymphoma, Mantle-Cell 6

Interventions

ARQ 197 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Osteolysis × Classical hematology × Clear all
NCT01447914 2019-08-28

Tivantinib in Treating Patients With Relapsed, or Relapsed and Refractory Multiple Myeloma

National Cancer Institute (NCI)

Phase 2 Completed
16 enrolled 11 charts
Classical hematologyOther hematologic neoplasmPlasma cell

Amyloidosis, Anemia, Bone Diseases, Metabolic, Fractures, Spontaneous, Hypercalcemia, Multiple Myeloma, Osteolysis, Paraproteinemias, Hematologic Neoplasms, Renal Insufficiency

Data powered by HemOnc (CC BY 4.0) Colophon âš¡